LLY

1,023.31

-0.06%↓

JNJ

199.38

+1.72%↑

ABBV

233.41

+0.45%↑

UNH

321.06

-0.1%↓

AZN

89.27

+0.15%↑

LLY

1,023.31

-0.06%↓

JNJ

199.38

+1.72%↑

ABBV

233.41

+0.45%↑

UNH

321.06

-0.1%↓

AZN

89.27

+0.15%↑

LLY

1,023.31

-0.06%↓

JNJ

199.38

+1.72%↑

ABBV

233.41

+0.45%↑

UNH

321.06

-0.1%↓

AZN

89.27

+0.15%↑

LLY

1,023.31

-0.06%↓

JNJ

199.38

+1.72%↑

ABBV

233.41

+0.45%↑

UNH

321.06

-0.1%↓

AZN

89.27

+0.15%↑

LLY

1,023.31

-0.06%↓

JNJ

199.38

+1.72%↑

ABBV

233.41

+0.45%↑

UNH

321.06

-0.1%↓

AZN

89.27

+0.15%↑

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Open

9.6 4.46

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.89

Max

9.9

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	79
EBITDA	4.5M -25M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+47.78% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	72M 659M
Vorige openingsprijs	5.14
Vorige sluitingsprijs	9.6

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 nov 2025, 17:45 UTC

Winsten

Belangrijke Marktbewegers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Winsten

Belangrijke Marktbewegers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 nov 2025, 23:40 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery -- Market Talk

16 nov 2025, 23:36 UTC

Marktinformatie

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 nov 2025, 23:26 UTC

Marktinformatie

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 nov 2025, 16:20 UTC

Winsten

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Marktinformatie

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Winsten

Acquisities, Fusies, Overnames

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Winsten

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Marktinformatie

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisities, Fusies, Overnames

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Marktinformatie

Winsten

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Marktinformatie

Winsten

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Marktinformatie

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Marktinformatie

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

47.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.67 USD 47.78%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.